Stock Events

Stock Events

Acumen Pharmaceuticals 

$2.68
39
-$0.06-2.1% 12:23 Today

Statistics

Day High
2.74
Day Low
2.74
52W High
3.6
52W Low
1.21
Volume
8,354
Avg. Volume
-
Mkt Cap
198.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.73
-0.59
-0.46
-0.33
Expected EPS
-0.381001
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-121.34MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ABOS. It's not an investment recommendation.
Amazon
7
AMZN
Schwab US Dividend Equity
7
SCHD
Microsoft
6
MSFT
Vanguard S&P 500
6
VOO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen is a leading biotech company in Alzheimer's disease research, directly competing with Acumen's focus on Alzheimer's therapeutics.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has advanced Alzheimer's disease treatments in its pipeline, making it a direct competitor to Acumen in the Alzheimer's space.
Anavex Life Sciences
AVXL
Mkt Cap298.48M
Anavex Life Sciences focuses on developing novel therapeutics for neurodegenerative diseases like Alzheimer's, positioning it as a competitor.
Prothena
PRTA
Mkt Cap454.85M
Prothena Corporation is engaged in the development of treatments for neurodegenerative diseases, including Alzheimer's, competing with Acumen's objectives.
Cass Information Systems
CASS
Mkt Cap748.01M
Cassava Sciences is working on the treatment of Alzheimer's disease, making it a competitor to Acumen in Alzheimer's research and development.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals, with its focus on RNA interference (RNAi) therapeutics, could potentially enter Alzheimer's or related markets, posing indirect competition.
Curis
CRIS
Mkt Cap4.37M
Curis, Inc. is involved in developing cancer treatments but its research into novel drug developments could pivot towards neurodegenerative diseases, offering indirect competition.

About

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Show more...
CEO
Daniel J. O'Connell
Employees
61
Country
United States
ISIN
US00509G2093

Listings

XNAS
US
ABOS
BOATS
BOATS
ABOS.BOATS

0 Comments

Share your thoughts

FAQ

What is Acumen Pharmaceuticals stock price today?▼
The current price of ABOS is $2.68 USD — it has decreased by -2.1% in the past 24 hours. Watch Acumen Pharmaceuticals stock price performance more closely on the chart.
What is Acumen Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Acumen Pharmaceuticals stocks are traded under the ticker ABOS.
Is Acumen Pharmaceuticals stock price growing?▼
ABOS stock has risen by +9.16% compared to the previous week, the month change is a +21.78% rise, over the last year Acumen Pharmaceuticals has showed a +98.55% increase.
What is Acumen Pharmaceuticals market cap?▼
Today Acumen Pharmaceuticals has the market capitalization of 198.15M
When is the next Acumen Pharmaceuticals earnings date?▼
Acumen Pharmaceuticals is going to release the next earnings report on November 16, 2026.
What were Acumen Pharmaceuticals earnings last quarter?▼
ABOS earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.36 USD resulting in a -25.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Acumen Pharmaceuticals revenue for the last year?▼
Acumen Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Acumen Pharmaceuticals net income for the last year?▼
ABOS net income for the last year is -121.34M USD.
How many employees does Acumen Pharmaceuticals have?▼
As of August 19, 2026, the company has 61 employees.
In which sector is Acumen Pharmaceuticals located?▼
Acumen Pharmaceuticals operates in the Health & Wellness sector.
When did Acumen Pharmaceuticals complete a stock split?▼
Acumen Pharmaceuticals has not had any recent stock splits.
Where is Acumen Pharmaceuticals headquartered?▼
Acumen Pharmaceuticals is headquartered in NEWTON, United States.